Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical lidocaine spray for postherpetic neuralgia
ACTRN12618000852257Phase 2Completed
- Sponsor
- Andros Pharmaceuticals Co., Ltd.
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing Lidocaine spray 5% solution with Placebo spray (2 arms). Primary endpoint: Change from baseline to Day 21 in pain intensity on NRS-11. Started Jul 2018; status: completed.
02
Drugs
lidocaine
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on ACTRN12618000852257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000852257.